Yahoo! Finance Canada report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
Why NVCR Stock advanced +0.31% Today — RQD Quant Desk Flash
NovoCure Limited (NVCR) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NVCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, NovoCure Limited (NASDAQ: NVCR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $13.15 (+0.31% 1D, market cap $1.53B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NVCR ranks #980 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NVCR compare to TNDM and ATEC in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), NVCR carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 74.5%, and ROIC of -27.5%. By comparison, TNDM (Tandem Diabetes Care Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $1.38B) and ATEC (Alphatec Holdings Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -18.4%, cap $1.76B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NVCR?
▼
Per NVCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001645113), NovoCure Limited generated $655.4M in revenue (+8.3% YoY), -$136.2M in net income, and -$75.7M in free cash flow against $804.3M in total assets and $195.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 0.54 (DISTRESS RISK (<1.8)) • Piotroski F-Score 6/9
20D Institutional Volume Accumulation (±11.6% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a NVCR Turnaround Squeeze
While NVCR currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($15.71) and Max Pain ($13.81) forces dealer call-delta covering toward $22.52.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why NVCR Stock advanced +0.31% Today — RQD Quant Desk Flash
NovoCure Limited (NVCR) advanced +0.31% to $13.15, trading at 29% of its 52-week range ($9.82 – $21.45). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 29% of its 52-week range ($9.82 – $21.45) with RSI-14 at 33.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.6% around $13.15 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 74.5% gross margin and $0 annual free cash flow.
Yahoo Finance Singapore report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
Japan's emergence as a second major market is offsetting headwinds in pancreatic cancer, testing whether geographic diversification can sustain growth.
NovoCure came into this Q3 2026 report with a bruised chart, down double digits over the past month, yet the stock barely moved today, up just 0.3% around US$13. That muted reaction sits awkwardly against a quarter that
Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Equal-Weight and lowers the price target from $20 to $15.
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NVCR)
- ✓Walkthrough of NVCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
NVCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NVCR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NVCR. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NVCR)
1. Head-to-Head Health Care Peer Comparison (NVCR vs. TNDM, ATEC, KMTS, BVS)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, NovoCure Limited (NVCR) ranks #980 by composite RQD confidence (21/100, grade E) and #304 by equity capitalization ($1.53B). Within this direct 5-issuer industry benchmark cohort, BVS leads on earnings valuation at 55.0x trailing P/E, while BVS leads on capital efficiency and profitability with 10.4% ROIC and 68.3% gross margin. BVS currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with NVCR at 21/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NVCR
ACTIVE
NovoCure Limited | E | 21/100 | — | 74.5% | -27.5% | +0.31% | $1.53B | Benchmark Subject |
| TNDM Tandem Diabetes Care Inc. | E | 30/100 | — | 53.8% | -35.0% | -3.44% | $1.38B | /tndm-vs-nvcr → |
| ATEC Alphatec Holdings Inc. | D | 46/100 | — | 69.6% | -18.4% | -38.08% | $1.76B | /atec-vs-nvcr → |
| KMTS Kestra Medical Technologies Ltd. | D | 50/100 | — | 51.4% | -35.0% | -3.01% | $1.82B | /kmts-vs-nvcr → |
| BVS Bioventus Inc. (Class A) | C | 65/100 | 55.0x | 68.3% | 10.4% | -10.39% | $1.25B | /bvs-vs-nvcr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001645113In its most recent audited fiscal period (FY2025, filed 2025-12-31), NovoCure Limited (NVCR) reported GAAP revenue of $655.4M (+8.3% vs. FY2024 revenue of $605.2M , and +28.7% cumulative change since FY2023) , GAAP net income of -$136.2M, operating cash flow of -$49.0M, and free cash flow of -$75.7M (-9.3% YoY). On the balance sheet, NVCR closed FY2025 with $804.3M in total assets against $195.0M in total debt (Altman Z-Score: 0.54, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $655.4M | -$136.2M | -$49.0M | -$75.7M | $804.3M | $195.0M |
| FY2024 (FY) | 2024-12-31 | $605.2M | -$169.0M | -$26.4M | -$69.2M | $1.24B | $97.3M |
| FY2023 (FY) | 2023-12-31 | $509.3M | -$207.0M | -$73.3M | -$73.3M | — | — |
3. NVCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NVCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, NovoCure Limited (NASDAQ: NVCR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $13.15 (+0.31% 1D, market cap $1.53B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NVCR ranks #980 in composite RQD confidence.
How does NVCR compare to TNDM and ATEC in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), NVCR carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 74.5%, and ROIC of -27.5%. By comparison, TNDM (Tandem Diabetes Care Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $1.38B) and ATEC (Alphatec Holdings Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -18.4%, cap $1.76B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NVCR?
Per NVCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001645113), NovoCure Limited generated $655.4M in revenue (+8.3% YoY), -$136.2M in net income, and -$75.7M in free cash flow against $804.3M in total assets and $195.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NVCR trading relative to its 50-day, 200-day, and 52-week technical levels?
NVCR last traded at $13.15 (+0.31% on volume of 1,974,532 shares), positioning the stock -16.30% below its 50-day simple moving average ($15.71) and -11.21% below its 200-day simple moving average ($14.81). Across its 52-week range of $9.82 to $21.45, NVCR sits at the 28.6% percentile with a 14-day RSI of 33.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($11.62 to $14.68).
NVCR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NVCR stock moving today?
Why NVCR Stock advanced +0.31% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
NVCR — NovoCure Limited: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, NVCR scores 21 out of 100 and carries a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 1 / 20 (ROIC -27.5%; FCF yield -4.96%), Whale 13F Flow at 5 / 20 (institutional accumulation and options positioning), Insider Conviction at 3 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 4 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8 / 20 (Altman Z 0.54; Piotroski F 6/9; Debt/Equity 0.57). For a prospective investor, the weakest pillar is the cash engine: the rating reflects negative return on invested capital and negative free cash flow yield, meaning the business is not currently generating returns on capital or cash in excess of its spending. The forensic balance sheet pillar sits in the low-middle range; an Altman Z of 0.54 is the metric the rating highlights as the principal distress flag, while the Piotroski F of 6/9 indicates a moderate set of positive fundamental signals. Flow and insider pillars are also low, indicating limited evidence of conviction from institutional or insider buyers in the source data. Macro fit is weak with a beta of 1.0, meaning the stock moves in line with the market rather than providing a defensive or differentiated profile. Taken together, the rating frames NVCR as a high-risk, cash-burning name where upside would depend on a sustained improvement in operating cash generation that the current data does not show. Valuation tradeoffs cannot be assessed on earnings multiples, since P/E and EPS are not available in source data; the investor must rely on the cash and balance sheet pillars, which both point to elevated risk.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $655.4M | $-153.8M | $-136.2M | N/A | $-75.7M | $93.5M | $195.0M |
| FY 2024 | $605.2M | $-170.5M | $-169.0M | N/A | $-69.2M | $163.8M | $97.3M |
| FY 2023 | $509.3M | $-232.9M | $-207.0M | N/A | $-73.3M | N/A | N/A |
Per the SEC financials, revenue rose from $509.3M in FY 2023 to $655.4M in FY 2025, while operating losses narrowed from $-232.9M to $-153.8M over the same span. Per the market data, the operating margin is -23.5%, the net margin is -20.8%, and ROIC is -27.5%. The Altman Z-Score is 0.54 and the Piotroski F-Score is 6/9, both per the Roarable RQD rating. Cash fell from $163.8M in FY 2024 to $93.5M in FY 2025 while debt rose from $97.3M to $195.0M, and the Debt/Equity ratio is 0.57 per the Roarable RQD rating.
Recent Catalysts & News Wire Analysis
Per the recent news data, six items reference NVCR. Four are general market-wire coverage from Yahoo! Finance Canada, Yahoo Finance Singapore, Seeking Alpha, and Simply Wall St, each flagged YELLOW. A TradingView item headlined a 12-month price target cut to $21.33 implying 62% upside is flagged RED under RISK WATCH. A marketscreener.com earnings flash reports a Q3 loss of $0.09 per share versus a FactSet estimate of a $0.23 loss, also flagged RED under RISK WATCH. The earnings item indicates a per-share result that beat the cited estimate, while the price-target item is a risk flag. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.
Open Questions
- What products and customers generate the $655.4M of FY 2025 revenue, and what drives the 74.5% gross margin?
- Why did cash decline from $163.8M to $93.5M and debt rise from $97.3M to $195.0M between FY 2024 and FY 2025, and what is the company's funding runway given negative free cash flow?
- What are the P/E, forward P/E, EV/EBITDA, and EPS values, which are absent from the source data and needed to assess valuation?
- What is the basis for the 12-month price target cut to $21.33, and which analysts issued it?
- Who are the 13F institutional holders and insiders, and what is their recent trading direction?
NVCR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for NovoCure Limited (NVCR) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Singapore report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering NovoCure Limited (NVCR) market action, institutional positioning, and fundamental catalysts.
Japan's emergence as a second major market is offsetting headwinds in pancreatic cancer, testing whether geographic diversification can sustain growth.
NVCR Bull vs. Bear Conversation Board — What's Your Call at $13.15?
🔥 Official Bull vs. Bear Debate: Is NVCR (E • RQD 21/100) a Buy at $13.11?
Welcome to the NVCR (NovoCure Limited) Roar Pit. Current RQD Composite is 21/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on NVCR — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on NVCR, but look at what you are paying: current EV/EBITDA multiples with 74.5% gross margins. Unless NovoCure Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
NVCR cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on NVCR, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $13.11 (52-wk range $9.82 - $21.45), any beat on forward guidance forces shorts and underweight funds to chase.